Design and Characterization of Prodrug-like Inhibitors for Preventing Glutamate Efflux through Reverse Transport
ACS Chemical Neuroscience · 2023
DOI: 10.1021/acschemneuro.3c00651 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2023. Verfasst von Laura J Zielewicz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Binghamton University, 4400 Vestal Parkway East, Binghamton, New York 13902, United States. Hauptthemen laut MEDLINE: Glutamic Acid, Prodrugs. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Glutamate transporters are responsible for active transport of the major excitatory neurotransmitter glutamate across the cell membrane, regulating the extracellular glutamate concentration in the mammalian brain. Extracellular glutamate levels in the brain are usually in the submicromolar range but can increase by exocytosis, inhibition of cellular uptake, or through glutamate release by reverse transport, as well as other mechanisms, which can lead to neurodegeneration and neuronal cell death. Such conditions can be encountered upon energy deprivation during an ischemic stroke. Here, we developed acetoxymethyl (AM) ester prodrug-like derivatives of excitatory amino acid transporter (EAAT) inhibitors that permeate the cell membrane and are activated, most likely through hydrolysis by endogenous cellular esterases, to form the active EAAT inhibitor. Upon increase in external K+ concentration, the inhibitors block glutamate efflux by EAAT reverse transport. Using a novel high-affinity fluorescent prodrug-like inhibitor, dl-threo-9-anthracene-methoxy-aspartate (TAOA) AM ester, we demonstrate that the precursor rapidly accumulates inside cells. Electrophysiological methods and fluorescence assays utilizing the iGluSnFR external glutamate sensor were used to demonstrate the efficacy of AM ester-protected inhibitors in inhibiting K+-mediated glutamate release. Together, our results provide evidence for a novel method to potentially prevent glutamate release by reverse transport under pathophysiological conditions in a model cell system, as well as in human astrocytes, while leaving glutamate uptake under physiological conditions operational. This method could have wide-ranging applications in the prevention of glutamate-induced neuronal cell death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Binghamton University, 4400 Vestal Parkway East, Binghamton, New York 13902, United States.
ORCID-Profile: Jiali Wang, Christof Grewer
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Zielewicz, L. J., Wang, J., Ndaru, E., Maney, B., Yu, X., Albers, T., & Grewer, C. (2023). Design and Characterization of Prodrug-like Inhibitors for Preventing Glutamate Efflux through Reverse Transport. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.3c00651
Vancouver
Zielewicz LJ, Wang J, Ndaru E, Maney B, Yu X, Albers T, et al. Design and Characterization of Prodrug-like Inhibitors for Preventing Glutamate Efflux through Reverse Transport. ACS Chemical Neuroscience. 2023. doi:10.1021/acschemneuro.3c00651
BibTeX
@article{Zielewicz2023,
author = {Zielewicz, Laura J and Wang, Jiali and Ndaru, Elias and Maney, Brien and Yu, Xiaozhen and Albers, Thomas and Grewer, Christof},
title = {Design and Characterization of Prodrug-like Inhibitors for Preventing Glutamate Efflux through Reverse Transport},
journal = {ACS Chemical Neuroscience},
year = {2023},
doi = {10.1021/acschemneuro.3c00651}
}
EUVIMED